TWiV 964: Clinical update with Dr. Daniel Griffin
b'
In his weekly clinical update Dr. Griffin\\xa0discusses\\xa0Dr. Griffin\\xa0discusses\\xa0progress toward poliomyelitis eradication in Afghanistan, reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons,\\xa0reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters,\\xa0authorized updated (Bivalent) COVID-19 vaccines for children down to 6 months of age,\\xa0low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster,\\xa0efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB,\\xa0incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir, and\\xa0the effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post\\u2013COVID-19 conditions.
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Progress toward\\xa0Poliomyelitis eradication\\xa0in Afghanistan (CDC)
- Reduced risk\\xa0for Mpox after receipt of 1 or 2 Doses of JYNNEOS vaccine (CDC)
- Reduced airborne transmission of\\xa0BA.1 Omicron virus\\xa0in Syrian hamsters (PLOS)
- Authorized bivalent vaccines\\xa0for children down to 6 months of age (FDA)
- Low neutralization of\\xa0BA.2.75.2, BQ.1.1, and XBB.1\\xa0by parental mRNA vaccine (Nature)
- Efficacy of antiviral agents\\xa0against Omicron subvariants BQ.1.1 and XBB (NEJM)
- Viral rebound after treatment with\\xa0Nirmatrelvir-Ritonavir and Molnupiravir\\xa0(JAMA)
- Paxlovid patient eligbiliity\\xa0screening checklist (FDA)
- Effectiveness\\xa0of COVID-19 vaccines in prevention of post\\u2013infection conditions (ASHE)
- Contribute to our\\xa0MicrobeTV fundraiser at PWB
- Dr. Griffin\\u2019s treatment guide (pdf)
- Letters read\\xa0on TWiV 964
- Timestamps by Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv